Replies to post #228884 on Biotech Values

[DewDiligence]

GILD-FTSV buyout price=96% premium to FTSV’s closing price on 2/27/20. (FTSV’s price on 2/28/20 was boosted by the report of buyout discussions by the Bloomberg newswire: #msg-154061400.)

https://finance.yahoo.com/news/gilead-acquire-forty-seven-4-115500794.html

[vinmantoo]

Jbog,

Definitely a nice premium for FTSV. I don't own as much FTSV as I do TRIL, but it will be a nice chunk of change. I was going to ask when the deal would be finalize but saw it was expected by sometime in the second quarter.

TRIL is already is getting yet another boost from FTSV but is coming off the highs earlier today. I don't think there will be much more upswing for TRIL until the phase I dosage escalation data comes in mid 2020 but who knows.

Could you provide some insight into IOVA you just mentioned?

[DewDiligence]

GILD discontinues phase-3 Magrolimab trial_in MDS for futility:

https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds

Magrolimab came to GILD via the 2020 acquisition of FTSV for $4.9B (#msg-154105690).